Receptor

Study: Bisphenol a exposure and major depressive disorder: an integrative analysis combining network toxicology, molecular docking, genetic epidemiology, and transcriptomic validation. Image Credit: monticello / Shutterstock

April 1, 2026

Researchers combined genetic epidemiology, transcriptomics, molecular docking, and mouse experiments to show how a common endocrine-disrupting chemical may…

HHealth

Patients who stop GLP-1 drugs often restart or try alternatives

March 17, 2026

A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or…

SScience

Nanostructures boost CRISPR delivery for genetic medicine

March 11, 2026

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can “educate” the…

HHealth

Research shows the potential of structural nanomedicine in cancer treatment

March 9, 2026

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by…

HHealth

New study links cystitis to higher risk of urogenital cancers

March 9, 2026

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ bleeding or clotting…

HHealth

Study: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. Image Credit: Kotcha K / Shutterstock

March 9, 2026

A major study of US veterans suggests that GLP-1 diabetes medications may influence addiction-related outcomes, revealing a surprising…

HHealth

Epigenetic editing enables safer and more effective T cell therapies

March 7, 2026

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists.…

HHealth

Review: GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Image Credit: Gecko Studio / Shutterstock

March 4, 2026

A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…

HHealth

Survey shows ongoing misconceptions about hormone therapy safety in cancer survivors

March 3, 2026

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is…

HHealth

Lifestyle changes show promise in preventing cognitive decline and Alzheimer’s disease

February 28, 2026

A new research paper was published in Volume 18 of Aging-US on February 6, 2026, titled “Causal effects of inflammation on…

SScience

Pioneering technology enables scalable production of human kidney organoids

February 28, 2026

Study reveals how two proteins cooperate in a key early step of antiviral detection, as reported by researchers…

TTechnology

Trial: Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial. Image Credit: Alones / Shutterstock

February 25, 2026

Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial of dapiglutide, researchers…

How could bisphenol A raise depression risk? Study identifies six key molecular targets

Patients who stop GLP-1 drugs often restart or try alternatives

Simplified nanoparticles “educate” the immune system to find and destroy disease-causing cells

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

Blocking growth hormone receptor may improve treatment response in lung cancer

Mendelian randomization study reveals opposing roles for IL6 and IL6R in long-term mortality

Protein partnership enhances innate immune sensing of viral RNA

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity